Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study.

Advances and applications in bioinformatics and chemistry : AABC

Hasan TN, B LG, Masoodi TA, Shafi G, Alshatwi AA, Sivashanmugham P.
PMID: 21918635
Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 08.

BACKGROUND: The human progesterone receptor (hPR) belongs to the steroid receptor family. It may be found as monomers (A and B) and or as a dimer (AB). hPR is regarded as the prognostic biomarker for breast cancer. In a...

Cite
Hasan TN, B LG, Masoodi TA, et al. Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem. 2011;4:29-36doi: 10.2147/AABC.S17371.
Hasan, T. N., B, L. G., Masoodi, T. A., Shafi, G., Alshatwi, A. A., & Sivashanmugham, P. (2011). Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Advances and applications in bioinformatics and chemistry : AABC, 429-36. https://doi.org/10.2147/AABC.S17371
Hasan, Tarique N, et al. "Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study." Advances and applications in bioinformatics and chemistry : AABC vol. 4 (2011): 29-36. doi: https://doi.org/10.2147/AABC.S17371
Hasan TN, B LG, Masoodi TA, Shafi G, Alshatwi AA, Sivashanmugham P. Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 08. PMID: 21918635; PMCID: PMC3169952.
Copy Download .nbib Format: NLM
Micellar electrokinetic capillary chromatography as an alternative method for the determination of ethinylestradiol and levo-norgestrel.

Talanta

Berzas JJ, Del Castillo B, Castañeda G, Pinilla MJ.
PMID: 18967716
Talanta. 1999 Sep 13;50(2):261-8. doi: 10.1016/s0039-9140(99)00030-2.

A method for quantifying of ethinylestradiol (ETE) and levo-norgestrel (LEV) in pharmaceutical products by micellar electrokinetic chromatography (MEKC) is described. The separation was carried out at 25 degrees C and 25 kV, using a 20 mM borate buffer (pH...

Cite
Berzas JJ, Del Castillo B, Castañeda G, et al. Micellar electrokinetic capillary chromatography as an alternative method for the determination of ethinylestradiol and levo-norgestrel. Talanta. 1999;50(2):261-8doi: 10.1016/s0039-9140(99)00030-2.
Berzas, J. J., Del Castillo, B., Castañeda, G., & Pinilla, M. J. (1999). Micellar electrokinetic capillary chromatography as an alternative method for the determination of ethinylestradiol and levo-norgestrel. Talanta, 50(2), 261-8. https://doi.org/10.1016/s0039-9140(99)00030-2
Berzas, J J, et al. "Micellar electrokinetic capillary chromatography as an alternative method for the determination of ethinylestradiol and levo-norgestrel." Talanta vol. 50,2 (1999): 261-8. doi: https://doi.org/10.1016/s0039-9140(99)00030-2
Berzas JJ, Del Castillo B, Castañeda G, Pinilla MJ. Micellar electrokinetic capillary chromatography as an alternative method for the determination of ethinylestradiol and levo-norgestrel. Talanta. 1999 Sep 13;50(2):261-8. doi: 10.1016/s0039-9140(99)00030-2. PMID: 18967716.
Copy Download .nbib Format: NLM
Low dietary folate impairs glucose tolerance and plasma lipid profile in oral contraceptive-treated rats.

Pathophysiology : the official journal of the International Society for Pathophysiology

Olatunji LA, Soladoye AO.
PMID: 18572393
Pathophysiology. 2008 Oct;15(3):167-71. doi: 10.1016/j.pathophys.2008.04.001. Epub 2008 Jun 24.

UNLABELLED: Estrogen-progestogen oral contraceptive (OC) use is associated with abnormal lipid metabolism, impaired glucose tolerance and high prevalence of vascular complications. OC use has been shown to alter the requirements for folic acid. Therefore, the aim of the present...

Cite
Olatunji LA, Soladoye AO. Low dietary folate impairs glucose tolerance and plasma lipid profile in oral contraceptive-treated rats. Pathophysiology. 2008;15(3):167-71doi: 10.1016/j.pathophys.2008.04.001.
Olatunji, L. A., & Soladoye, A. O. (2008). Low dietary folate impairs glucose tolerance and plasma lipid profile in oral contraceptive-treated rats. Pathophysiology : the official journal of the International Society for Pathophysiology, 15(3), 167-71. https://doi.org/10.1016/j.pathophys.2008.04.001
Olatunji, L A, and Soladoye, A O. "Low dietary folate impairs glucose tolerance and plasma lipid profile in oral contraceptive-treated rats." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 15,3 (2008): 167-71. doi: https://doi.org/10.1016/j.pathophys.2008.04.001
Olatunji LA, Soladoye AO. Low dietary folate impairs glucose tolerance and plasma lipid profile in oral contraceptive-treated rats. Pathophysiology. 2008 Oct;15(3):167-71. doi: 10.1016/j.pathophys.2008.04.001. Epub 2008 Jun 24. PMID: 18572393.
Copy Download .nbib Format: NLM
Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Patient preference and adherence

Benagiano G, Carrara S, Filippi V.
PMID: 19936155
Patient Prefer Adherence. 2009 Nov 03;3:131-43. doi: 10.2147/ppa.s3692.

The progestational steroid norgestrel was synthesized and tested between 1960 and 1965 through an international cooperation between Wyeth, USA and Schering, Berlin. It is a mixture of two "enantiomers," with only one form (designated as levonorgestrel) biologically active. When...

Cite
Benagiano G, Carrara S, Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence. 2009;3:131-43doi: 10.2147/ppa.s3692.
Benagiano, G., Carrara, S., & Filippi, V. (2009). Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient preference and adherence, 3131-43. https://doi.org/10.2147/ppa.s3692
Benagiano, Giuseppe, et al. "Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives." Patient preference and adherence vol. 3 (2009): 131-43. doi: https://doi.org/10.2147/ppa.s3692
Benagiano G, Carrara S, Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence. 2009 Nov 03;3:131-43. doi: 10.2147/ppa.s3692. PMID: 19936155; PMCID: PMC2778424.
Copy Download .nbib Format: NLM
Luteal blood flow in patients undergoing GnRH agonist long protocol.

Journal of ovarian research

Takasaki A, Tamura I, Kizuka F, Lee L, Maekawa R, Asada H, Taketani T, Tamura H, Shimamura K, Morioka H, Sugino N.
PMID: 21219663
J Ovarian Res. 2011 Jan 11;4(1):2. doi: 10.1186/1757-2215-4-2.

BACKGROUND: Blood flow in the corpus luteum (CL) is closely related to luteal function. It is unclear how luteal blood flow is regulated. Standardized ovarian-stimulation protocol with a gonadotropin-releasing hormone agonist (GnRHa long protocol) causes luteal phase defect because...

Cite
Takasaki A, Tamura I, Kizuka F, et al. Luteal blood flow in patients undergoing GnRH agonist long protocol. J Ovarian Res. 2011;4(1):2doi: 10.1186/1757-2215-4-2.
Takasaki, A., Tamura, I., Kizuka, F., Lee, L., Maekawa, R., Asada, H., Taketani, T., Tamura, H., Shimamura, K., Morioka, H., & Sugino, N. (2011). Luteal blood flow in patients undergoing GnRH agonist long protocol. Journal of ovarian research, 4(1), 2. https://doi.org/10.1186/1757-2215-4-2
Takasaki, Akihisa, et al. "Luteal blood flow in patients undergoing GnRH agonist long protocol." Journal of ovarian research vol. 4,1 (2011): 2. doi: https://doi.org/10.1186/1757-2215-4-2
Takasaki A, Tamura I, Kizuka F, Lee L, Maekawa R, Asada H, Taketani T, Tamura H, Shimamura K, Morioka H, Sugino N. Luteal blood flow in patients undergoing GnRH agonist long protocol. J Ovarian Res. 2011 Jan 11;4(1):2. doi: 10.1186/1757-2215-4-2. PMID: 21219663; PMCID: PMC3024996.
Copy Download .nbib Format: NLM
Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-Only Pill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study.

JMIR research protocols

Edelman A, Hemon A, Creinin M, Borensztein P, Scherrer B, Glasier A.
PMID: 33970869
JMIR Res Protoc. 2021 Jun 08;10(6):e29208. doi: 10.2196/29208.

BACKGROUND: Progestin-only contraceptive pills (POP) are commonly reserved for women with medical comorbidities but in actuality, POPs can be safely used by anyone wanting to prevent pregnancy. This wide safety profile makes them an ideal candidate for being available...

Cite
Edelman A, Hemon A, Creinin M, et al. Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-Only Pill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study. JMIR Res Protoc. 2021;10(6):e29208doi: 10.2196/29208.
Edelman, A., Hemon, A., Creinin, M., Borensztein, P., Scherrer, B., & Glasier, A. (2021). Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-Only Pill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study. JMIR research protocols, 10(6), e29208. https://doi.org/10.2196/29208
Edelman, Alison, et al. "Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-Only Pill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study." JMIR research protocols vol. 10,6 (2021): e29208. doi: https://doi.org/10.2196/29208
Edelman A, Hemon A, Creinin M, Borensztein P, Scherrer B, Glasier A. Assessing the Pregnancy Protective Impact of Scheduled Nonadherence to a Novel Progestin-Only Pill: Protocol for a Prospective, Multicenter, Randomized, Crossover Study. JMIR Res Protoc. 2021 Jun 08;10(6):e29208. doi: 10.2196/29208. PMID: 33970869; PMCID: PMC8262664.
Copy Download .nbib Format: NLM
Female body mass index and the selection of a long-acting reversible contraception for the first time.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Frederico G, Silva Dos Santos PN, Ferreira JM, Bahamondes L, Fernandes A.
PMID: 34939199
Int J Gynaecol Obstet. 2021 Dec 22; doi: 10.1002/ijgo.14081. Epub 2021 Dec 22.

OBJECTIVE: To evaluate Brazilian women with different body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) values who were switching from a short-acting reversible contraceptive (SARC) to a long-acting reversible contraceptive...

Cite
Frederico G, Silva Dos Santos PN, Ferreira JM, et al. Female body mass index and the selection of a long-acting reversible contraception for the first time. Int J Gynaecol Obstet. 2021;doi: 10.1002/ijgo.14081.
Frederico, G., Silva Dos Santos, P. N., Ferreira, J. M., Bahamondes, L., & Fernandes, A. (2021). Female body mass index and the selection of a long-acting reversible contraception for the first time. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, . https://doi.org/10.1002/ijgo.14081
Frederico, Giulia, et al. "Female body mass index and the selection of a long-acting reversible contraception for the first time." International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics vol. (2021). doi: https://doi.org/10.1002/ijgo.14081
Frederico G, Silva Dos Santos PN, Ferreira JM, Bahamondes L, Fernandes A. Female body mass index and the selection of a long-acting reversible contraception for the first time. Int J Gynaecol Obstet. 2021 Dec 22; doi: 10.1002/ijgo.14081. Epub 2021 Dec 22. PMID: 34939199.
Copy Download .nbib Format: NLM
Oral contraceptive administration aggravates nitric oxide synthesis inhibition-induced high blood pressure in female rats.

Pathophysiology : the official journal of the International Society for Pathophysiology

Olatunji LA, Soladoye AO.
PMID: 18977125
Pathophysiology. 2008 Dec;15(4):221-6. doi: 10.1016/j.pathophys.2008.09.001. Epub 2008 Oct 31.

UNLABELLED: The use of estrogen-progestogen oral contraceptive (OC) is associated with high blood pressure, although mechanisms responsible are still unclear. This study sought to investigate the effects of administration of OC on high blood pressure resulting from nitric oxide...

Cite
Olatunji LA, Soladoye AO. Oral contraceptive administration aggravates nitric oxide synthesis inhibition-induced high blood pressure in female rats. Pathophysiology. 2008;15(4):221-6doi: 10.1016/j.pathophys.2008.09.001.
Olatunji, L. A., & Soladoye, A. O. (2008). Oral contraceptive administration aggravates nitric oxide synthesis inhibition-induced high blood pressure in female rats. Pathophysiology : the official journal of the International Society for Pathophysiology, 15(4), 221-6. https://doi.org/10.1016/j.pathophys.2008.09.001
Olatunji, L A, and Soladoye, A O. "Oral contraceptive administration aggravates nitric oxide synthesis inhibition-induced high blood pressure in female rats." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 15,4 (2008): 221-6. doi: https://doi.org/10.1016/j.pathophys.2008.09.001
Olatunji LA, Soladoye AO. Oral contraceptive administration aggravates nitric oxide synthesis inhibition-induced high blood pressure in female rats. Pathophysiology. 2008 Dec;15(4):221-6. doi: 10.1016/j.pathophys.2008.09.001. Epub 2008 Oct 31. PMID: 18977125.
Copy Download .nbib Format: NLM
Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.

American journal of obstetrics and gynecology

Burchardt NA, Eliassen AH, Shafrir AL, Rosner B, Tamimi R, Kaaks R, Tworoger SS, Fortner RT.
PMID: 34921803
Am J Obstet Gynecol. 2021 Dec 15; doi: 10.1016/j.ajog.2021.12.022. Epub 2021 Dec 15.

BACKGROUND: Oral contraceptive (OC) use has been associated with higher breast cancer risk; however, evidence on the associations between different OC formulations and breast cancer risk, especially by disease subtype, is limited.OBJECTIVE: To evaluate associations between OC use by...

Cite
Burchardt NA, Eliassen AH, Shafrir AL, et al. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study. Am J Obstet Gynecol. 2021;doi: 10.1016/j.ajog.2021.12.022.
Burchardt, N. A., Eliassen, A. H., Shafrir, A. L., Rosner, B., Tamimi, R., Kaaks, R., Tworoger, S. S., & Fortner, R. T. (2021). Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study. American journal of obstetrics and gynecology, . https://doi.org/10.1016/j.ajog.2021.12.022
Burchardt, Norah A, et al. "Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study." American journal of obstetrics and gynecology vol. (2021). doi: https://doi.org/10.1016/j.ajog.2021.12.022
Burchardt NA, Eliassen AH, Shafrir AL, Rosner B, Tamimi R, Kaaks R, Tworoger SS, Fortner RT. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study. Am J Obstet Gynecol. 2021 Dec 15; doi: 10.1016/j.ajog.2021.12.022. Epub 2021 Dec 15. PMID: 34921803.
Copy Download .nbib Format: NLM
Emergency Contraception: More Than A Morning After Pill.

Medscape women's health

Creinin MD.
PMID: 9746623
Medscape Womens Health. 1996 Apr;1(4):1.

Emergency contraception (postcoital contraception, the "morning-after pill") has been available for almost 30 years but remains vastly underutilized. As many as 50% of undesired pregnancies could be prevented with the use of emergency contraception. Currently used regimens include ethinyl...

Cite
Creinin MD. Emergency Contraception: More Than A Morning After Pill. Medscape Womens Health. 1996;1(4):1
Creinin, M. D. (1996). Emergency Contraception: More Than A Morning After Pill. Medscape women's health, 1(4), 1.
Creinin. "Emergency Contraception: More Than A Morning After Pill." Medscape women's health vol. 1,4 (1996): 1.
Creinin MD. Emergency Contraception: More Than A Morning After Pill. Medscape Womens Health. 1996 Apr;1(4):1. PMID: 9746623.
Copy Download .nbib Format: NLM
Role of the levonorgestrel intrauterine system in effective contraception.

Patient preference and adherence

Attia AM, Ibrahim MM, Abou-Setta AM.
PMID: 23990713
Patient Prefer Adherence. 2013 Aug 09;7:777-85. doi: 10.2147/PPA.S36948. eCollection 2013.

Norgestrel, a synthetic progestin chemically derived from 19-nortestosterone, is six times more potent than progesterone, with variable binding affinity to various steroid receptors. The levonorgestrel-releasing intrauterine system (LNG IUS) provides a long-acting, highly effective, and reversible form of contraception,...

Cite
Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence. 2013;7:777-85doi: 10.2147/PPA.S36948.
Attia, A. M., Ibrahim, M. M., & Abou-Setta, A. M. (2013). Role of the levonorgestrel intrauterine system in effective contraception. Patient preference and adherence, 7777-85. https://doi.org/10.2147/PPA.S36948
Attia, Abdelhamid M, et al. "Role of the levonorgestrel intrauterine system in effective contraception." Patient preference and adherence vol. 7 (2013): 777-85. doi: https://doi.org/10.2147/PPA.S36948
Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence. 2013 Aug 09;7:777-85. doi: 10.2147/PPA.S36948. eCollection 2013. PMID: 23990713; PMCID: PMC3749061.
Copy Download .nbib Format: NLM
Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems.

Pharmaceutical research

Brewster ME, Estes KS, Bodor N.
PMID: 24271710
Pharm Res. 1986 Oct;3(5):278-85. doi: 10.1023/A:1016359301852.

Dihydropyridine ⇄ pyridinium salt-based brain-selective delivery systems were synthesized for the progestins, ethisterone, norethindrone, and norgestrel. After initial lipophilicity and in vitro studies indicated the feasibility of applying these compounds to brain-specific delivery, in vivo distribution studies were performed...

Cite
Brewster ME, Estes KS, Bodor N. Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems. Pharm Res. 1986;3(5):278-85doi: 10.1023/A:1016359301852.
Brewster, M. E., Estes, K. S., & Bodor, N. (1986). Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems. Pharmaceutical research, 3(5), 278-85. https://doi.org/10.1023/A:1016359301852
Brewster, M E, et al. "Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems." Pharmaceutical research vol. 3,5 (1986): 278-85. doi: https://doi.org/10.1023/A:1016359301852
Brewster ME, Estes KS, Bodor N. Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems. Pharm Res. 1986 Oct;3(5):278-85. doi: 10.1023/A:1016359301852. PMID: 24271710.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries